Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai Henlius Biotech, Inc.
上海復宏漢霖生物技術股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2696)

VOLUNTARY ANNOUNCEMENT

THE PHASE 1 CLINICAL TRIAL OF HLX109 INJECTION (A MONOCLONAL ANTIBODY TARGETING IL1RAP) FOR THE TREATMENT OF GENERALIZED PUSTULAR PSORIASIS HAS BEEN APPROVED TO COMMENCE IN AUSTRALIA

A. INTRODUCTION

This announcement is made by Shanghai Henlius Biotech, Inc. (the "**Company**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business development of the Company.

The board of directors of the Company (the "**Board**") is pleased to announce that, recently, the phase 1 clinical trial application for HLX109 injection (a monoclonal antibody targeting IL1RAP) ("**HLX109**"), independently developed by the Company, for the treatment of generalized pustular psoriasis has been approved by the relevant Human Research Ethics Committee and acknowledged by the Therapeutic Goods Administration (TGA) of Australia.

B. ABOUT HLX109

HLX109 is a monoclonal antibody targeting IL1RAP developed independently by the Company, intended for the treatment of generalized pustular psoriasis. IL1RAP (IL-1 receptor accessory protein) is a key co-receptor in the receptor signaling complexes of inflammation-related cytokines such as IL-1, IL-33, and IL-36. HLX109 specifically binds to IL1RAP and blocks its recruitment to the ligand-receptor complexes formed by IL-1, IL-33, and IL-36 with their respective receptors, thereby inhibiting the formation of intact signaling complexes and the activation of downstream inflammatory signaling pathways. Preclinical studies have demonstrated that HLX109 exhibits anti-inflammatory effects and possesses a favorable safety profile.

C. MARKET CONDITION

As of the date of this announcement, no monoclonal antibody targeting IL1RAP has been approved for marketing globally.

WARNING STATEMENT WITH REFERENCE TO THE REQUIREMENTS UNDER RULE 18A.05 OF THE RULES GOVERNING THE LISTING OF SECURITIES ON THE STOCK EXCHANGE OF HONG KONG LIMITED: The Company cannot guarantee the successful development and commercialization of HLX109. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Xingli Wang
Chairman

Hong Kong, 4 November 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. Xingli Wang as the chairman and non-executive director, Dr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yuqing Chen, Ms. Xiaohui Guan and Dr. Yi Liu as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan and Dr. Ruilin Song as the independent non-executive directors.